Agenus - AGEN Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AGEN shares.
View AGEN analyst ratings or view top-rated stocks.

4 brokers have issued 1-year price objectives for Agenus' stock. Their AGEN share price forecasts range from $5.00 to $8.30. On average, they anticipate the company's stock price to reach $7.33 in the next twelve months. This suggests a possible upside of 385.1% from the stock's current price.
View analysts price targets for AGEN or view top-rated stocks among Wall Street analysts.

Agenus' stock was trading at $2.40 at the beginning of the year. Since then, AGEN stock has decreased by 37.1% and is now trading at $1.51.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our AGEN earnings forecast.

Agenus Inc. (NASDAQ:AGEN) announced its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported $0.69 EPS for the quarter, topping analysts' consensus estimates of $0.46 by $0.23. The biotechnology company had revenue of $252.95 million for the quarter, compared to analyst estimates of $183.11 million. Agenus had a negative net margin of 235.30% and a negative trailing twelve-month return on equity of 1,159.04%. During the same period in the previous year, the firm posted ($0.28) EPS.

ETFs with the largest weight of Agenus (NASDAQ:AGEN) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), WisdomTree BioRevolution Fund (WDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Future Gen 200 ETF (QQQS) and Principal Healthcare Innovators ETF (BTEC).

2 employees have rated Agenus Chief Executive Officer Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among the company's employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include (ROSG) (ROSG), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), OPKO Health (OPK), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Gilead Sciences (GILD), Matinas BioPharma (MTNB) and RedHill Biopharma (RDHL).

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Agenus' stock is owned by many different retail and institutional investors. Top institutional shareholders include Artal Group S.A. (4.76%), Point72 Asset Management L.P. (2.93%), Geode Capital Management LLC (1.72%), Renaissance Technologies LLC (1.27%), Charles Schwab Investment Management Inc. (0.69%) and Lindbrook Capital LLC (0.44%). Insiders that own company stock include Agenus Inc, Christine M Klaskin, Corp Incyte, Garo H Armen and Steven J O'day.
View institutional ownership trends.

Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AGEN stock can currently be purchased for approximately $1.51.

Agenus (NASDAQ:AGEN) has a market capitalization of $502.09 million and generates $98.02 million in revenue each year. The biotechnology company earns $-220,070,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

The company employs 441 workers across the globe.

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The official website for the company is agenusbio.com. The biotechnology company can be reached via phone at (781) 674-4400, via email at investor@agenusbio.com, or via fax at 781-674-4200.